专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2004096979A2 METHODS AND SYSTEMS FOR ANNOTATING BIOMOLECULAR SEQUENCES 审中-公开
标题翻译：生物分子序列的方法和系统
公开(公告)号：WO2004096979A2
公开(公告)日：2004-11-11
申请号：PCT/IL2004000077
申请日：2004-01-27
申请人： COMPUGEN LTD , MINTZ LIAT , XIE HANQING , DAHARY DVIR , LEVANON EREZ , FREILICH SHIRI , BECK NILI , ZHU WEI-YONG , WASSERMAN ALON , CHERMESH CHEN , AZAR IDIT , BERNSTEIN JEANNE , SOREK ROTEM
发明人： MINTZ LIAT , XIE HANQING , DAHARY DVIR , LEVANON EREZ , FREILICH SHIRI , BECK NILI , ZHU WEI-YONG , WASSERMAN ALON , CHERMESH CHEN , AZAR IDIT , BERNSTEIN JEANNE , SOREK ROTEM
IPC分类号： C12N20060101 , C12Q1/68 , G01N33/48 , G01N33/50 , G06F19/00 , C12N
CPC分类号： G06F19/12 , G06F19/22
摘要： A method of annotating biomolecular sequences. The method comprises (a) computationally clustering the biomolecular sequences according to a progressive homology range, to thereby generate a plurality of clusters each being of a predetermined homology of the homology range; and (b) assigning at least one ontology to each cluster of the plurality of clusters, the at least one ontology being: (i) derived from an annotation preassociated with at least one biomolecular sequence of each cluster; and/or (ii) generated from analysis of the at least one biomolecular sequence of each cluster thereby annotating biomolecular sequences.
摘要翻译：注释生物分子序列的方法。该方法包括（a）根据渐进同源范围计算聚集生物分子序列，从而产生多个具有同源范围的预定同源性的簇; 所述至少一个本体是：（i）从与每个簇的至少一个生物分子序列预先相关联的注释导出的;以及（b）将至少一个本体分配给所述多个簇中的每个簇，和/或（ii）从每个簇的至少一个生物分子序列的分析产生，从而注释生物分子序列。

22. 发明申请

WO2003070768A2 CD40 SPLICE VARIANTS, COMPOSITIONS FOR MAKING AND METHODS OF USING THE SAME 审中-公开
标题翻译： CD40 SPLICE VARIANTS，制备的组合物及其使用方法
公开(公告)号：WO2003070768A2
公开(公告)日：2003-08-28
申请号：PCT/IB2003/000665
申请日：2003-02-24
申请人： COMPUGEN LTD. , BERNSTEIN, Jeanne , MINTZ, Liat , ESHEL, Dani
发明人： BERNSTEIN, Jeanne , MINTZ, Liat , ESHEL, Dani
IPC分类号： C07K14/705
CPC分类号： C07K16/2878 , A61K48/00 , C07K14/70578 , C12N2799/026
摘要： Substantially pure CD40 splice variants which include unique tail sequences, fragments thereof comprising at least 10 amino acids including at least 4 amino acids of the unique tail sequence; the unique tail sequences, and homologues thereof having at least 10 amino acids and 90% identity and antibodies which bind to an epitope on such proteins are disclosed. Pharmaceutical composition comprising such protein, antibodies, isolated nucleic acid molecule that encode such proteins and pharmaceutical composition comprising such nucleic acid molecules are disclosed. The present invention relates to recombinant expression vectors which comprise such nucleic acid molecules and host cells which comprise such recombinant expression vectors are disclosed. In vitro methods of detecting in a sample the presence and/or quantity of such proteins or transcript which encodes such proteins are disclosed as are kits and reagents for performing the methods. Methods of modulating CD40-CD154 interactions in an individual are disclosed.
摘要翻译：基本上纯的CD40剪接变体，其包括唯一的尾部序列，其片段包含至少10个氨基酸，包括唯一尾部序列的至少4个氨基酸; 公开了具有至少10个氨基酸和90％同一性的独特的尾部序列及其同源物，并且与这些蛋白质上的表位结合的抗体。公开了包含这种蛋白质，抗体，编码这种蛋白质的分离的核酸分子和包含这种核酸分子的药物组合物的药物组合物。本发明涉及包含这种核酸分子的重组表达载体和包含这种重组表达载体的宿主细胞。在样本中检测体外的方法，公开了编码这种蛋白质的这些蛋白质或转录物的存在和/或数量，作为用于进行该方法的试剂盒和试剂。公开了调节个体中CD40-CD154相互作用的方法。

23. 发明申请

WO2022165275A8 COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS AND ANTI-PD-1 ANTIBODIES 审中-公开
公开(公告)号：WO2022165275A8
公开(公告)日：2022-08-04
申请号：PCT/US2022/014445
申请日：2022-01-28
申请人： COMPUGEN LTD. , BRISTOL-MYERS SQUIBB COMPANY , BARBIRO, Inbal , VAKNIN, Ilan , WOOL, Assaf , LEVINE, Zurit , BASCIANO, Paul, A. , LAMON, Brian, D.
发明人： ADEWOYE, Adeboye, Henry , HUNTER, John , COHEN-DAYAG, Anat , COJOCARU, Gad, S. , OPHIR, Eran , ALTEBER, Zoya
IPC分类号： A61P35/00 , C07K16/28 , A61K39/00 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/2818 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/90 , C07K2317/94
摘要： The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof. The present invention also provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.

24. 发明申请

WO2022069940A1 COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS, ANTI-TIGIT ANTIBODIES, AND ANTI-PD-1 ANTIBODIES 审中-公开
公开(公告)号：WO2022069940A1
公开(公告)日：2022-04-07
申请号：PCT/IB2021/000665
申请日：2021-09-30
申请人： COMPUGEN LTD.
发明人： ADEWOYE, Adeboye, Henry
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
摘要： The present invention is directed to combination treatments with anti-PVRIG antibodies, anti-TIGIT antibodies, and anti -PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.

25. 发明申请

WO2017066714A1 ANTI-VSIG1 ANTIBODIES AND DRUG CONJUGATES 审中-公开
标题翻译：抗VSIG1抗体和药物偶联物
公开(公告)号：WO2017066714A1
公开(公告)日：2017-04-20
申请号：PCT/US2016/057231
申请日：2016-10-14
申请人： COMPUGEN LTD. , DRAKE, Andrew, W.
发明人： DRAKE, Andrew, W. , POW, Andrew , HANSEN, Kyle , BENITA, Yair , COJOCARU, Gad, S. , SAMEAH-GREENWALD, Shirley
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2803 , A61K47/6803 , A61K47/6873 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/55 , C07K2317/73 , C07K2317/92 , G01N33/57423 , G01N33/57446 , G01N33/57449 , G01N2333/705
摘要： The disclosure relates generally to compounds with anti-cancer activity and more specifically to antibodies conjugated with chemotherapeutic drugs or toxins. The disclosure also relates to methods of using antibody-drug conjugate compounds for in vitro, in situ , and in vivo diagnosis or treatment of specific cancers.
摘要翻译：本公开一般涉及具有抗癌活性的化合物，并且更具体地涉及与化学治疗药物或毒素缀合的抗体。本公开还涉及在体外，原位和体内诊断或治疗特定癌症中使用抗体 - 药物缀合物化合物的方法。

26. 发明申请

WO2016134333A9 ANTI-PVRIG ANTIBODIES AND METHODS OF USE 审中-公开
标题翻译：抗PVRIG抗体和使用方法
公开(公告)号：WO2016134333A9
公开(公告)日：2017-02-02
申请号：PCT/US2016018809
申请日：2016-02-19
申请人： COMPUGEN LTD
发明人： WHITE MARK , KUMAR SANDEEP , CHAN CHRISTOPHER , LIANG SPENCER , STAPLETON LANCE , DRAKE ANDREW W , GOZLAN YOSI , VAKNIN IIAN , SAMEAH-GREENWALD SHIRLEY , DASSA LIAT , TIRAN ZOHAR , COJOCARU GAD S
IPC分类号： A61K38/00 , C07K14/00 , C07K16/28 , C12N15/113
CPC分类号： C07K16/2803 , C07K7/06 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/70 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/32 , C12N15/1138 , C12N2310/14 , G01N33/57484 , G01N2333/47
摘要： The present invention is directed to anti-PVRIG antibodies and methods of using same.
摘要翻译：本发明涉及抗PVRIG抗体及其使用方法。

27. 发明申请

WO2015037000A1 VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES 审中-公开
标题翻译： VSTM5多肽及其作为治疗癌症，感染性疾病和免疫相关疾病的药物的用途
公开(公告)号：WO2015037000A1
公开(公告)日：2015-03-19
申请号：PCT/IL2014050809
申请日：2014-09-11
申请人： COMPUGEN LTD
发明人： LEVINE ZURIT , ROTMAN GALIT , DASSA LIAT , LEVY OFER , COJOCARU GAD S , TOPORIK AMIR , KLIGER YOSSEF , VAKNIN ILAN , HECHT IRIS
IPC分类号： A61K38/17 , C07K7/00 , C07K14/435 , C07K19/00 , G01N33/50 , G01N33/564 , G01N33/569 , G01N33/574
CPC分类号： C07K14/705 , A61K31/675 , A61K38/00 , A61K39/39 , A61K45/06 , C07K2319/00 , C07K2319/30 , C07K2319/31 , G01N33/564 , G01N33/569 , G01N33/574 , G01N33/57492 , G01N2333/4703 , G01N2333/705 , A61K2300/00
摘要： This invention relates to VSTM5 proteins, soluble molecules and fusions thereof which are suitable targets for drug development and for treatment of immune related disorders, immunotherapy, treatment of cancer, infectious disorders and/or sepsis.
摘要翻译：本发明涉及VSTM5蛋白，可溶性分子及其融合物，它们是用于药物开发和治疗免疫相关疾病，免疫治疗，癌症治疗，感染性疾病和/或败血症的合适靶标。

28. 发明申请

WO2012140627A1 POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER 审中-公开
标题翻译：多肽和多核苷酸及其用于治疗免疫相关疾病和癌症的用途
公开(公告)号：WO2012140627A1
公开(公告)日：2012-10-18
申请号：PCT/IB2012/051868
申请日：2012-04-16
申请人： COMPUGEN LTD. , TOPORIK, Amir , NOVIK, Amit , SHEMESH, Ronen
发明人： TOPORIK, Amir , NOVIK, Amit , SHEMESH, Ronen
IPC分类号： C07K14/705 , C07K14/715 , A61K39/00
CPC分类号： C07K14/70503 , A61K38/00 , A61K38/1774 , A61K39/0008 , A61K39/001 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C07K2319/43 , C12N2760/10022 , C12N2760/16121 , C12N2770/32031 , G01N33/53 , G01N33/57484 , G01N33/577 , G01N2333/47 , Y02A50/412 , Y02A50/423
摘要： This invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble LY6G6F, VSIG10, TMEM25 and LSR molecules, extracellular domains of LY6G6F, VSIG10, TMEM25 and LSR and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders. This invention further relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LY6G6F, VSIG10, TMEM25 or LSR molecules, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.
摘要翻译：本发明涉及LY6G6F，VSIG10，TMEM25和LSR蛋白，其是免疫治疗，癌症治疗，感染性疾病和/或免疫相关病症以及药物开发的合适靶标。本发明还涉及可溶性LY6G6F，VSIG10，TMEM25和LSR分子，LY6G6F，VSIG10，TMEM25和LSR的细胞外结构域和缀合物，其是用于免疫治疗，治疗癌症，感染性疾病和/或免疫相关疾病的合适的药物。本发明还涉及对于LY6G6F，VSIG10，TMEM25或LSR分子具有特异性的抗体和抗原结合片段和含有其的缀合物和/或替代性支架，其是用于免疫治疗，癌症治疗，感染性疾病和/或免疫的合适的药物相关疾病。

29. 发明申请

WO2012110999A1 GENETIC MARKERS FOR PROGNOSIS OF RHEUMATOID ARTHRITIS TREATMENT EFFICACY 审中-公开
标题翻译：用于预防湿疹病毒治疗效果的遗传标记
公开(公告)号：WO2012110999A1
公开(公告)日：2012-08-23
申请号：PCT/IL2012/000073
申请日：2012-02-12
申请人： COMPUGEN LTD , PINCHAS, Akiva , EDELHEIT-FLOHR, Sarit , BAZAK, Lily , LEVINE, Zurit , TOPORIK, Amir , LEVY, Ofer , ZEKHARYA, Tomer , WOOL, Assaf
发明人： PINCHAS, Akiva , EDELHEIT-FLOHR, Sarit , BAZAK, Lily , LEVINE, Zurit , TOPORIK, Amir , LEVY, Ofer , ZEKHARYA, Tomer , WOOL, Assaf
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The present invention discloses markers useful in predicting the responsiveness of a subject having, or at risk of developing rheumatoid arthritis (RA) to treatment with anti- TNFα agents. Particularly, the present invention discloses the allelic configuration of the CD6 gene and/or the STXBP6 gene which is indicative of the degree of responsiveness to anti-TNFα treatment of RA.
摘要翻译：本发明公开了用于预测具有或具有发展类风湿性关节炎（RA）的风险的受试者对抗TNFα剂治疗的反应性的标记。特别地，本发明公开了CD6基因和/或STXBP6基因的等位基因构型，其指示针对RA的抗TNFα治疗的反应程度。

30. 发明申请

WO2012090150A2 NEW CELL-PENETRATING PEPTIDES AND USES THEREOF 审中-公开
标题翻译：新细胞穿刺肽及其用途
公开(公告)号：WO2012090150A2
公开(公告)日：2012-07-05
申请号：PCT/IB2011/055956
申请日：2011-12-26
申请人： COMPUGEN LTD , JACOB, Etail , TOPORIK, Amir , SHEMESH, Ronen , LEVY, Ofer
发明人： JACOB, Etail , TOPORIK, Amir , SHEMESH, Ronen , LEVY, Ofer
IPC分类号： A61K47/48
CPC分类号： A61K47/48246 , A61K47/62 , C07K14/47 , C07K14/78 , C07K2319/01
摘要： The present invention is related to peptides, which are suitable for use as cell-penetrating peptides (CPPs), variants thereof and/or complexes, fusion molecules and/or conjugates comprising same, use thereof for manufacture of compositions for diagnosing, treating and/or preventing of medical conditions.
摘要翻译：本发明涉及适合用作细胞穿透肽（CPP），其变体和/或复合物，包含其的融合分子和/或缀合物的肽，其用于制备用于诊断，治疗和/ 或预防医疗状况。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式